El Hadad, Jasmina
Schreiner, Philipp
Vavricka, Stephan R.
Greuter, Thomas
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2ZHP3_168561)
University of Zurich
Article History
Accepted: 26 September 2023
First Online: 17 October 2023
Declarations
:
: Open access funding provided by University of Zurich. This work was supported by a grant from the Swiss National Science Foundation to Thomas Greuter (Grant no. P2ZHP3_168561). This work was further supported by a young investigator award from the Swiss Society of Gastroenterology to Thomas Greuter, a research grant from the Novartis Foundation for Medical-Biological Research to Thomas Greuter, a research award from the Swiss IBDnet to TG, and a research grant from the EoE Foundation to Thomas Greuter.
: Philipp Schreiner has received fees for consulting from AbbVie, Galapagos, Lilly, Sanofi-Regeneron, Falk Pharma, Ferring, Pfizer, Janssen, and Takeda. Stephan R. Vavricka has received consulting fees and unrestricted research grants from Abbott, Falk Pharma GmbH, Ferring Pharmaceuticals, Janssen, MSD, Pfizer Inc, Sanofi-Aventis, Takeda, Tillotts, UCB, and Vifor. Thomas Greuter has consulting contracts with Sanofi-Regeneron, Bristol-Myers Squibb, Takeda, AbbVie, and Falk Pharma GmbH, received travel grants from Falk Pharma GmbH and Vifor, speaker’s fees from Norgine and Amgen, and an unrestricted research grant from Novartis. Jasmina El Hadad has no conflicts of interest that are directly relevant to the content of this article. No company representative was involved in the conception, writing, or financing of this study.
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: JE: drafting manuscript; PS: drafting manuscript and critical review; SRV: drafting manuscript and critical review; TG: drafting manuscript and critical review, responsible investigator.